Used primarily as a potent and selective inhibitor of fibroblast growth factor receptor (FGFR) kinases, particularly FGFR1, FGFR2, and FGFR3. It is investigated for its antitumor activity in cancers driven by FGFR genetic alterations, such as urothelial carcinoma, cholangiocarcinoma, and certain types of lung and breast cancers. The compound demonstrates strong efficacy in blocking FGFR signaling pathways, leading to inhibition of cancer cell proliferation, induction of apoptosis, and suppression of tumor growth in preclinical models. It has advanced into clinical trials for patients with advanced solid tumors harboring FGFR mutations or fusions, showing promise as a targeted therapy with manageable side effects. Its design allows for improved selectivity and reduced off-target effects compared to earlier kinase inhibitors.